TrialBreast cancer (Tokyo, Japan)2018

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.

Xavier Pivot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.